- Home
- PGEN vs OMCL Comparison
PGEN vs OMCL Comparison
Compare PGEN & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | OMCL |
|---|---|---|
| Founded | 1998 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PGEN | OMCL |
|---|---|---|
| Price | $3.81 | $41.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $8.33 | ★ $55.83 |
| AVG Volume (30 Days) | ★ 4.0M | 409.7K |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $230,981,000.00 | ★ $787,309,000.00 |
| Revenue This Year | $1,115.92 | $6.77 |
| Revenue Next Year | $81.04 | $5.22 |
| P/E Ratio | ★ N/A | $167.64 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $1.30 | $26.85 |
| 52 Week High | $5.47 | $51.84 |
Technical Indicators
Market Signals| Indicator | PGEN | OMCL |
|---|---|---|
| Relative Strength Index (RSI) | 38.10 | 45.30 |
| Support Level | $3.49 | $32.20 |
| Resistance Level | $4.40 | $45.11 |
| Average True Range (ATR) | 0.29 | 1.50 |
| MACD | -0.07 | -0.50 |
| Stochastic Oscillator | 2.97 | 13.73 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.